- Calithera Biosciences Inc CALA and Antengene Corporation Ltd have announced an exclusive, worldwide license agreement for the development and commercialization of CB-708.
- CB-708 is a highly potent, selective, orally-bioavailable small molecule inhibitor of CD73, currently in preclinical development for oncology.
- Under the terms of the license agreement, Calithera will receive an upfront payment and potential milestone payments of up to $255 million.
- Additionally, Calithera is eligible to receive tiered royalties on sales of the licensed product up to low double-digits.
- Price Action: CALA shares are up 6.7% at $2.17 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
